IOVA
Income statement / Annual
Last year (2024), Iovance Biotherapeutics, Inc.'s total revenue was $164.07 M,
an increase of 13,698.99% from the previous year.
In 2024, Iovance Biotherapeutics, Inc.'s net income was -$372.18 M.
See Iovance Biotherapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$164.07 M |
$1.19 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$124.00 M
|
$10.76 M
|
$0.00
|
$0.00
|
$0.00
|
$8.12 M
|
$956.00 K
|
$952.00 K
|
$978.00 K
|
$999.00 K
|
| Gross Profit |
$40.08 M
|
-$9.57 M
|
$0.00
|
$0.00
|
$0.00
|
-$8.12 M
|
-$956.00 K
|
-$952.00 K
|
-$978.00 K
|
-$999.00 K
|
| Gross Profit Ratio |
0.24
|
-8.05
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$282.34 M
|
$344.08 M
|
$294.78 M
|
$259.04 M
|
$201.73 M
|
$166.02 M
|
$99.83 M
|
$71.62 M
|
$28.04 M
|
$15.47 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$104.10 M
|
$83.66 M
|
$60.21 M
|
$40.85 M
|
$28.43 M
|
$21.26 M
|
$25.60 M
|
$12.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$153.02 M
|
$106.92 M
|
$104.10 M
|
$83.66 M
|
$60.21 M
|
$40.85 M
|
$28.43 M
|
$21.26 M
|
$17.20 M
|
$12.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.50 M
|
$0.00
|
| Operating Expenses |
$435.35 M
|
$450.99 M
|
$398.88 M
|
$342.70 M
|
$261.94 M
|
$206.87 M
|
$128.26 M
|
$92.88 M
|
$53.64 M
|
$27.86 M
|
| Cost And Expenses |
$559.35 M
|
$461.75 M
|
$398.88 M
|
$342.70 M
|
$261.94 M
|
$206.87 M
|
$128.26 M
|
$92.88 M
|
$53.64 M
|
$27.86 M
|
| Interest Income |
$20.27 M
|
$13.04 M
|
$2.99 M
|
$451.00 K
|
$2.36 M
|
$9.32 M
|
$0.00
|
$813.00 K
|
$745.00 K
|
$200.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$2.99 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$200.00 K
|
| Depreciation & Amortization |
$43.61 M
|
$33.13 M
|
$21.14 M
|
$13.98 M
|
$1.14 M
|
$8.12 M
|
$956.00 K
|
$952.00 K
|
$978.00 K
|
$999.00 K
|
| EBITDA |
-$351.67 M |
-$427.43 M |
-$377.74 M |
-$328.72 M |
-$260.80 M |
-$189.43 M |
-$122.62 M |
-$91.11 M |
-$51.92 M |
-$26.66 M |
| EBITDA Ratio |
-2.14
|
-359.49
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.41
|
-387.35
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$20.27 M
|
$13.04 M
|
$2.99 M
|
$451.00 K
|
$2.36 M
|
$9.32 M
|
$4.68 M
|
$813.00 K
|
$745.00 K
|
$200.00 K
|
| Income Before Tax |
-$375.01 M
|
-$447.52 M
|
-$395.89 M
|
-$342.25 M
|
-$259.58 M
|
-$197.56 M
|
-$123.58 M
|
-$92.06 M
|
-$52.89 M
|
-$27.66 M
|
| Income Before Tax Ratio |
-2.29
|
-376.38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.83 M
|
-$3.48 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$372.18 M
|
-$444.04 M
|
-$395.89 M
|
-$342.25 M
|
-$259.58 M
|
-$197.56 M
|
-$123.58 M
|
-$92.06 M
|
-$52.89 M
|
-$27.66 M
|
| Net Income Ratio |
-2.27
|
-373.45
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.28 |
-1.89 |
-2.49 |
-2.23 |
-1.88 |
-1.5 |
-1.27 |
-1.41 |
-0.96 |
-0.62 |
| EPS Diluted |
-1.28 |
-1.89 |
-2.49 |
-2.23 |
-1.88 |
-1.5 |
-1.27 |
-1.41 |
-0.96 |
-0.62 |
| Weighted Average Shares Out |
$289.88 M
|
$235.13 M
|
$159.26 M
|
$153.41 M
|
$138.30 M
|
$124.34 M
|
$97.28 M
|
$65.24 M
|
$55.27 M
|
$44.41 M
|
| Weighted Average Shares Out Diluted |
$289.88 M
|
$235.13 M
|
$159.26 M
|
$153.41 M
|
$138.30 M
|
$124.34 M
|
$97.28 M
|
$65.24 M
|
$55.27 M
|
$44.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
